Allogene Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

ALLO$0.93-12.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Collaboration revenue - related party	$—	$—	$—	$22
Operating expenses:
Research and development	31,164	44,713	121,520	147,327
General and administrative	13,737	16,333	43,009	49,687
Impairment of long-lived assets	—	10,728	2,382	15,717
Total operating expenses	44,901	71,774	166,911	212,731
Loss from operations	(44,901)	(71,774)	(166,911)	(212,709)
Other income (expense), net:
Interest and other income, net	3,926	6,705	15,629	17,126
Interest expense	(344)	(100)	(762)	(100)
Other income (expenses), net	(81)	(1,124)	(32)	(1,968)
Total other income (expense), net	3,501	5,481	14,835	15,058
Net loss	(41,400)	(66,293)	(152,076)	(197,651)
Other comprehensive loss:
Net unrealized gain (loss) on available-for-sale investments	280	937	324	1,112
Net comprehensive loss	$(41,120)	$(65,356)	$(151,752)	$(196,539)
Net loss per share, basic and diluted	$(0.19)	$(0.32)	$(0.70)	$(1.04)
Weighted-average number of shares used in computing net loss per share, basic and diluted	222,038,680	209,188,551	218,800,085	189,519,897

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.